ANVS Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's dise…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. | ||
 Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA Annovis Bio (NYSE:ANVS) said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer’s disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements | ||